[특허]Long term drug delivery devices with polyurethane-based polymers and their manufacture

Endo Pharmaceuticals Solutions Inc.

검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
검색연산자

검색도움말
검색연산자	기능	검색시 예
()	우선순위가 가장 높은 연산자	예1) (나노 (기계 \| machine))
공백	두 개의 검색어(식)을 모두 포함하고 있는 문서 검색	예1) (나노 기계) 예2) 나노 장영실
\|	두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색	예1) (줄기세포 \| 면역) 예2) 줄기세포 \| 장영실
!	NOT 이후에 있는 검색어가 포함된 문서는 제외	예1) (황금 !백금) 예2) !image
*	검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색	예) semi*
""	따옴표 내의 구문과 완전히 일치하는 문서만 검색	예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기

내보내기 페이스북 공유 트위터 공유 카카오톡 공유

Long term drug delivery devices with polyurethane-based polymers and their manufacture

특허상세정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	A61F-002/00 A61K-009/00
미국특허분류(USC)	424/423; 606/194; 604/890.1
출원번호	US-0892946 (2013-05-13)
등록번호	US-8784865 (2014-07-22)
발명자 / 주소	Kuzma, Petr Quandt, Harry
출원인 / 주소	Endo Pharmaceuticals Solutions Inc.
대리인 / 주소	RatnerPrestia
인용정보	피인용 횟수 : 0 인용 특허 : 33

초록

This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

대표
청구항
▼

1. An implantable drug delivery device, comprising a polyurethane-based polymer having polyether-based polyol segments represented by the formula —[O—(CH2)n]x—O—, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases as the equilibrium water content (% EWC) of the polymer increases, wherein the active agent is histrelin, risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline. 2. The drug delivery device of claim 1, wherein the active agent is histrelin. 3. The drug delivery device of claim 1, wherein the active agent is risperidone. 4. The drug delivery device of claim 1, wherein the active agent is dexamethasone. 5. The drug delivery device of claim 1, wherein the active agent is naltrexone. 6. The drug delivery device of claim 1, wherein the active agent is metolazone. 7. The drug delivery device of claim 1, wherein the active agent is clonidine. 8. The drug delivery device of claim 1, wherein the active agent is selegiline. 9. The drug delivery device of claim 1, wherein the polyurethane-based polymer has a % EWC of between about 5%-43%. 10. The drug delivery device of claim 1, wherein the one or more pharmaceutically acceptable carriers is selected from the group consisting of croscarmellose, stearic acid, and a combination thereof. 11. The drug delivery device of claim 10, wherein the one or more pharmaceutically acceptable carriers are croscarmellose and stearic acid. 12. The drug delivery device of claim 11, wherein the croscarmellose comprises 10% of the solid drug formulation, and stearic acid comprises 2% of the solid drug formulation. 13. The drug delivery device of claim 1, wherein the reservoir has a wall thickness of 0.2 mm. 14. A method of delivering an active agent to a subject, comprising implanting an implantable device into the subject, wherein the implantable device comprises a polyurethane-based polymer having polyether-based polyol segments represented by the formula —[O—(CH2)n]x—O—, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases as the equilibrium water content (% EWC) of the polymer increases, wherein the active agent is histrelin, risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline. 15. The method of claim 14, wherein the active agent is histrelin. 16. The method of claim 14, wherein the active agent is risperidone. 17. The method of claim 14, wherein the active agent is dexamethasone. 18. The method of claim 14, wherein the active agent is naltrexone. 19. The method of claim 14, wherein the active agent is metolazone. 20. The method of claim 14, wherein the active agent is clonidine. 21. The method of claim 14, wherein the active agent is selegiline. 22. The method of claim 14, wherein the polyurethane-based polymer has a % EWC of between about 5%-43%. 23. The method of claim 14, wherein the one or more pharmaceutically acceptable carriers is selected from the group consisting of croscarmellose, stearic acid, and a combination thereof. 24. The method of claim 23, wherein the one or more pharmaceutically acceptable carriers are croscarmellose and stearic acid. 25. The method device of claim 24, wherein the croscarmellose comprises 10% of the solid drug formulation, and stearic acid comprises 2% of the solid drug formulation. 26. The method of claim 14, wherein the reservoir has a wall thickness of 0.2 mm. 27. A process for manufacturing a drug delivery device comprising: supplying a polyurethane-based polymer formed as a hollow tube; loading a solid formulation comprising one or more active ingredients into the tube; and sealing the tube; wherein the one or more active ingredients and the polyurethane-based polymer are selected such that either: (i) both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophilic characteristics, or (ii) both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophobic characteristics; and wherein the drug delivery device delivers the one or more active ingredients by diffusion through the polyurethane-based polymer at a substantially zero order release rate in vitro and wherein the polyurethane-based polymer is formed from one or more polyols, wherein the general polyol structure is selected from the group consisting of: —[O—(CH2)n]x—O—;O—(CH2—CH2—CH2—CH2)x—O—; andO—[(CH2)6—CO3]n—(CH2)—O—. 28. The process of claim 27, wherein the sealing of the hollow tube comprises inserting a pre-fabricated plug into an open end and applying heat or solvent to the pre-fabricated plug and polyurethane-based polymer. 29. The process of claim 27, wherein the sealing comprises inserting a pre-fabricated end plug at an open end of the hollow tube; applying an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation into an interface formed between the pre-fabricated end plug and the open end; and curing the polyurethane formulation with light and/or heat to seal the pre-fabricated plug in the end of the tube. 30. The process of claim 27 further comprising conditioning and priming comprises selecting a parameter selected from the group consisting of time, temperature, and medium to influence the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer. 31. The process of claim 27, wherein the one or more active ingredients and the polyurethane-based polymer are selected such that both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophilic characteristics. 32. The process of claim 27, wherein the one or more active ingredients and the polyurethane-based polymer are selected such that both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophobic characteristics. 33. The process of claim 27, wherein the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer. 34. The process of claim 33, wherein the one or more pharmaceutically acceptable carriers are not required for the substantially zero order release rate in vitro of the one or more active ingredients as governed by Fick's Law of Diffusion. 35. The process of claim 27, wherein the hollow tube is formed by extrusion molding, injection molding, or spin-casting of the polyurethane-based polymer. 36. The process of claim 27, wherein the hollow tube is formed with two open ends. 37. The process of claim 27, wherein the hollow tube is formed with two open ends, and one end is sealed prior to the loading. 38. The process of claim 27, wherein the hollow tube is formed with one open end and one closed end. 39. The process of claim 31 in which the at least one active ingredient is selected from drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, and antiparasitic. 40. The process of claim 32 in which the at least one active ingredient is selected from drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, and antiparasitic. 41. The process of claim 27, wherein the at least one active ingredient is selected from the group consisting of histrelin, risperidone, dexamethasone, naltrexone, metolazone, clonidine, and selegiline.

인용문헌 (33)

IPC 상위 출원인

내보내기

상세정보
내보내기 구분	파일저장 인쇄 메일전송
구성항목	관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	> 총 건의 자료가 검색되었습니다. > 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) > 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. > 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) > 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오 > ~ > Text(ASCII format) Excel format

과학기술 지식인프라 ScienceON

ScienceON Chatbot

연합인증

특허 상세정보

Long term drug delivery devices with polyurethane-based polymers and their manufacture

초록

대표
청구항
▼

인용문헌 (33)

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

ScienceON Chatbot

연합인증

특허 상세정보

Long term drug delivery devices with polyurethane-based polymers and their manufacture

초록

대표청구항 ▼

인용문헌 (33)

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

대표
청구항
▼